Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||clear cell renal cell carcinoma||not applicable||Cediranib + Saracatinib||Phase II||Actionable||In a Phase II clinical trial, Saracatinib (AZD0530) did not increase the efficacy of Recentin (cediranib) in patients with metastatic clear-cell renal cell carcinoma (n=69 for both trial arms) (PMID: 26802156).||26802156|